Germany’s Fresenius Kabi, a business segment of health care group Fresenius has acquired the Intravenously Administered (I.V.) business of Dabur Pharma for € 139 million  ($219 million)

Dabur Pharma is one of the leading suppliers of generic drugs and active pharmaceutical ingredients (API) to treat cancer. The company holds a substantial number of drug registrations in Asia, Europe and the US. Dabur Pharma is also one of the few manufacturers worldwide to hold international registrations for all steps within the manufacturing process of cytostatic agents. Dabur Pharma operates two production facilities in India and one in Great Britain as well as a research and development center equipped in accordance with European and US standards near New Delhi.

Fresenius Kabi’s acquisition of 73.3 percent share of the Dabur Pharma is part of its continuous growth strategy in I.V. drugs business. Fresenius Kabi has entered into an agreement with a third party to secure the participation of 2.4 % of Dabur Pharma's share capital in the public offer.

Dabur Pharma founder and director Anand Burman said, “To drive the future growth of the company, it was important to integrate with somebody who has global reach and who could expedite the growth of the company. I honestly believe the deal is in the best interest of the business and the people involved in the business.”

The acquisition significantly expands Fresenus Kabi’s I.V. drug portfolio and secures its supply of high quality APIs for cytostatics. With the acquisition of Dabur Pharma, Fresenius Kabi will also broaden its offering of patient-specific oncology therapies. In future, Dabur Pharma will supply Fresenius Kabi’s compounding centers in Europe, Asia-Pacific and Latin America where patient-specific formulations of I.V. drugs and parenteral nutrition are being prepared for cancer patients.